BPC-157 is a synthetic pentadecapeptide related to a peptide sequence described from human gastric juice, and its human research base currently centers on small pilot or observational studies, registered clinical trials, and safety/regulatory questions rather than mature clinical efficacy evidence (Review).
BPC-157 is most often discussed in relation to tissue repair, pain, bladder symptoms, and peptide pharmacology, but the published human evidence remains very limited compared with the larger animal and experimental literature (Review). Human studies include a retrospective knee-pain chart review, a small interstitial-cystitis pilot study, a 2-person IV safety pilot, and registered oral or muscle-injury trials rather than large replicated randomized efficacy trials (Research) (Research). Numerical pharmacokinetic data are available mainly from animal ADME research, where BPC-157 showed rapid elimination and a reported half-life generally under 30 minutes after IV and IM dosing, but these values should not be treated as confirmed human half-life data (Research).
Ingredient Identity
- Official name(s): BPC-157; Body Protection Compound 157.
- Common research name: Stable gastric pentadecapeptide BPC-157.
- Classification: Synthetic peptide / pentadecapeptide.
- CAS number: 137525-51-0.
- Endogenous vs exogenous: BPC-157 is described in reviews as related to a peptide sequence isolated from human gastric juice, but products referred to as BPC-157 in research and commerce are synthetic peptide preparations (Review).
- Primary evidence type: Preclinical evidence is much larger than the human evidence base, and the verified human literature is mostly small, uncontrolled, pilot-level, or registry-based (Review).
Ingredient Snapshot
- Classification: BPC-157 is a synthetic pentadecapeptide studied mainly in experimental tissue-repair, pain, and safety contexts (Review).
- Endogenous vs exogenous status: Reviews describe BPC-157 as related to a peptide sequence from human gastric juice, while research preparations are synthetic peptide forms (Review).
- Primary human research domains: The available human literature includes Joint Health, Urinary Health, Muscle Health trial registration, Pain and Acute Inflammation discussion, and short-term IV safety monitoring (Research) (Research) (Research).
- Common study formats: Published human evidence includes a retrospective chart review, small pilot studies, and trial-registration records rather than multiple completed randomized efficacy trials (Research) (Research).
- Pharmacokinetic characterization status: Human Tmax, human oral bioavailability, and human plasma half-life were not verified in accessible peer-reviewed PK publications, while animal ADME research reports rapid elimination and half-life generally under 30 minutes (Research).
- Regulatory context (U.S./EU): The FDA has identified BPC-157 among bulk drug substances that may present significant safety risks when used in compounding, including immunogenicity and peptide-quality concerns (FDA). A direct EMA or EFSA authorization source specific to BPC-157 was not verified for this article, so EU status is described cautiously rather than as a specific authorization finding.
- Evidence maturity: The overall human evidence base is best classified as Emerging because published human studies are few, small, and not yet supported by multiple large replicated trials (Review).
Introduction
BPC-157 is a short peptide made of 15 amino acids and is described in the literature as a stable gastric pentadecapeptide related to a sequence isolated from human gastric juice (Review). In practical research contexts, BPC-157 is studied as a synthetic peptide preparation rather than as a conventional dietary nutrient or ordinary food-derived ingredient (Review).
People often look up BPC-157 because of claims around tissue repair, musculoskeletal recovery, bladder symptoms, and peptide pharmacology, but the human evidence remains much thinner than the animal literature (Review). Verified human evidence includes a retrospective knee-pain chart review, a small interstitial-cystitis pilot study, a 2-person IV safety pilot, and trial registrations rather than a large body of replicated randomized clinical trials (Research) (Research).
This article is informational only, describes BPC-157 as a biochemical substance studied in human research, and does not provide medical or dosing advice.
Quick Summary
- BPC-157 is a synthetic 15-amino-acid peptide related to a gastric peptide sequence, and it is not supported by a mature human clinical evidence base (Review).
- The strongest numerical pharmacokinetic data for BPC-157 come from animal ADME research, where IV and IM elimination was rapid and half-life was generally reported as under 30 minutes (Research).
- Human Joint Health evidence includes one retrospective knee-pain chart review in which most followed patients reported improvement, but the study lacked a randomized placebo control and standardized functional outcomes (Research).
- Human Urinary Health evidence includes a small interstitial-cystitis pilot study reporting symptom improvement, but the study remains preliminary and does not establish broad clinical efficacy (Research).
- A 2-person IV pilot safety study reported no short-term side effects or major biomarker changes, but this sample size is too small to characterize general safety (Research).
- The FDA has identified BPC-157 as a compounded-substance safety concern because of immunogenicity and peptide-related quality risks (FDA).
- Overall evidence is Emerging because human studies are few, small, and not yet supported by multiple large randomized trials (Review).
Human Research Findings by Condition
Joint Health
Human Joint Health evidence for BPC-157 is limited mainly to a retrospective knee-pain chart review rather than randomized controlled trials (Research). Orthopaedic reviews describe the human evidence base as sparse and dominated by preclinical research, so knee-related findings should be interpreted as preliminary (Review).
Key human study
Dose studied: Local intra-articular clinical exposure; the article should be consulted for procedural details rather than used as dosing guidance.
Population: 17 clinic patients in a retrospective review; 16 were followed up, and 12 received BPC-157 alone.
Duration: Follow-up varied, with many follow-ups occurring months after injection.
Lee and Padgett reviewed clinic records from patients who received BPC-157 injections for knee pain and reported that 11 of 12 patients receiving BPC-157 alone had significant improvement in knee pain (Research). The study was uncontrolled, retrospective, and based on clinical follow-up rather than randomized assignment or blinded outcome measurement (Research).
Result: Observational human studies reported an association
Evidence strength: Observational
Study source: (Research)
Additional human study
Dose studied: Not applicable as an efficacy trial; review-level synthesis.
Population: Orthopaedic sports medicine literature.
Duration: Not applicable.
A systematic review in orthopaedic sports medicine found that BPC-157 evidence is mostly animal-based and identified only limited human clinical evidence relevant to orthopaedic contexts (Review). This review supports treating the knee-pain chart review as hypothesis-generating rather than confirmatory evidence (Review).
Result: Human evidence remains limited or inconclusive
Evidence strength: Limited
Study source: (Review)
Urinary Health
Human Urinary Health evidence includes a small interstitial-cystitis pilot study, which reported symptom improvement after intravesical BPC-157 exposure (Research). Because the study was small and preliminary, it should not be interpreted as established treatment evidence (Research).
Key human study
Dose studied: Intravesical clinical exposure; this is a research context, not dosing guidance.
Population: 12 patients with interstitial cystitis.
Duration: Pilot follow-up period reported in the study.
The interstitial-cystitis pilot study reported symptom improvement in patients receiving intravesical BPC-157, including high rates of reported relief in the small cohort (Research). The study’s small size and pilot design limit confidence in generalizability, durability, and comparative efficacy (Research).
Result: Human clinical study reported a modest improvement
Evidence strength: Emerging
Study source: (Research)
Additional human study
Dose studied: Not applicable as a direct urinary efficacy trial; review-level synthesis.
Population: Review literature covering BPC-157 tissue-repair and pain contexts.
Duration: Not applicable.
A tissue-repair and pain-management review summarized the small interstitial-cystitis report but treated the human evidence base as very limited overall (Review). This supports describing Urinary Health evidence as preliminary rather than established (Review).
Result: Human evidence remains limited or inconclusive
Evidence strength: Limited
Study source: (Review)
Muscle Health
Human Muscle Health evidence is currently represented by trial-registration evidence rather than completed published efficacy results (Research). A registered Phase 2 trial was designed to study BPC-157 in acute grade II hamstring strain, but a trial registry record should not be treated as completed proof of benefit (Research).
Key human study
Dose studied: Registered trial intervention; registry details should not be used as dosing guidance.
Population: Adults with acute grade II hamstring strain.
Duration: 14-day intervention with follow-up endpoints.
The registered trial record describes a randomized, double-blind, placebo-controlled Phase 2 study evaluating BPC-157 for acute hamstring muscle strain, including return-to-sport and MRI-based injury-volume endpoints (Research). Because the source is a registry record, it establishes trial intent and design but not completed clinical efficacy (Research).
Result: Human evidence remains limited or inconclusive
Evidence strength: Emerging
Study source: (Research)
Additional human study
Dose studied: Not applicable as a completed human efficacy trial; review-level synthesis.
Population: Musculoskeletal healing literature.
Duration: Not applicable.
A musculoskeletal healing review concluded that BPC-157 remains investigational because human clinical data are minimal despite substantial preclinical interest (Review). This supports classifying Muscle Health evidence as early and not yet clinically mature (Review).
Result: Human evidence remains limited or inconclusive
Evidence strength: Limited
Study source: (Review)
Pain and Acute Inflammation
Human Pain and Acute Inflammation evidence overlaps with knee-pain and bladder-pain reports, but it has not yet been established through large replicated pain trials (Research) (Research). Reviews describe BPC-157 as a tissue-repair and pain-management candidate while emphasizing that human evidence remains limited (Review).
Key human study
Dose studied: Local intra-articular clinical exposure; not dosing guidance.
Population: Patients receiving BPC-157 injection for knee pain in a retrospective review.
Duration: Follow-up occurred over variable clinical intervals.
The knee-pain chart review reported pain improvement in most followed patients receiving BPC-157 alone, but the study design cannot separate the effect of BPC-157 from placebo effects, regression to the mean, concurrent care, or natural recovery (Research). This makes the pain-related signal observational and preliminary (Research).
Result: Observational human studies reported an association
Evidence strength: Observational
Study source: (Research)
Additional human study
Dose studied: Intravesical clinical exposure; not dosing guidance.
Population: 12 patients with interstitial cystitis.
Duration: Pilot follow-up period.
The interstitial-cystitis pilot study reported symptom relief in a small bladder-pain population, but the evidence remains pilot-level and does not define broader pain efficacy (Research). This evidence is best interpreted as a preliminary human signal in a specific urinary-pain context (Research).
Result: Human clinical study reported a modest improvement
Evidence strength: Emerging
Study source: (Research)
Digestive and Gastrointestinal Health
BPC-157 is biologically associated with gastric peptide research, but verified human Digestive and Gastrointestinal Health outcome evidence remains limited in the source set used for this article (Review). FDA materials show that BPC-157-related compounding discussions have included ulcerative colitis as an evaluated use context, but regulatory discussion is not clinical evidence of efficacy (FDA).
Key human study
Dose studied: Not applicable as a completed published efficacy study.
Population: Regulatory evaluation context rather than a published treatment cohort.
Duration: Not applicable.
The FDA Pharmacy Compounding Advisory Committee meeting page lists BPC-157-related bulk substances for discussion and includes ulcerative colitis as the evaluated-use context (FDA). This source supports only the existence of a regulatory discussion context, not a conclusion that BPC-157 is effective for ulcerative colitis or other gastrointestinal conditions (FDA).
Result: Human evidence remains limited or inconclusive
Evidence strength: Emerging
Study source: (FDA)
Additional human study
Dose studied: Oral exposure in a registered safety/PK trial; not dosing guidance.
Population: Healthy adult volunteers planned in a Phase 1 oral safety/PK study.
Duration: Three-week subject participation listed in the trial record.
The PCO-02 trial record describes a randomized placebo-controlled oral safety and pharmacokinetics study in healthy adults, but accessible peer-reviewed completed PK or efficacy results were not verified for this article (Research). This trial record is relevant to oral exposure and pharmacokinetic research, but it does not establish Digestive and Gastrointestinal Health outcomes (Research).
Result: Human evidence remains limited or inconclusive
Evidence strength: Emerging
Study source: (Research)
Dosage & Study Snapshot (Research Context)
Human BPC-157 studies and trial records involve local, IV, oral, and registered muscle-injury contexts, but the published evidence does not support practical dosing guidance. Numerical pharmacokinetic values are clearest in animal ADME research, not verified human plasma PK publications. The exposure summaries below describe what was studied or registered and should not be read as use instructions.
Oral exposure in registered Phase 1 safety/PK research:
A registered Phase 1 trial record described oral BPC-157 safety and pharmacokinetic testing in healthy adult volunteers, with the record listing a planned randomized placebo-controlled study and three-week subject participation (Research). The record is useful because it shows that oral PK was formally planned, but peer-reviewed completed human Tmax, half-life, and oral bioavailability values were not verified in the source set used here (Research). This means oral timing fields should be presented as not established in accessible human PK publications. The trial record should not be used as evidence of efficacy.
Result: Inconclusive
Evidence strength: Emerging
Notes / limitations: A trial-registration or trial-listing record describes study design, not confirmed published clinical results.
Intravesical clinical exposure in interstitial cystitis:
A small pilot study reported intravesical BPC-157 exposure in 12 patients with interstitial cystitis (Research). The study reported symptom improvement, but it did not establish systemic absorption, plasma half-life, Tmax, or route-specific bioavailability (Research). This route is clinically relevant to Urinary Health research, but the evidence remains preliminary because the study was small. The timing of symptom change should not be equated with pharmacokinetic onset or duration.
Result: Preliminary signal
Evidence strength: Emerging
Notes / limitations: Symptom follow-up does not define systemic pharmacokinetics.
Intra-articular clinical exposure in knee pain:
A retrospective chart review evaluated BPC-157 injections in patients with knee pain and reported improvement in most followed patients receiving BPC-157 alone (Research). The study was observational and did not establish systemic bioavailability, dose-response, plasma half-life, or pharmacologic onset (Research). This exposure context is relevant to Joint Health, but the absence of randomization and standardized controls limits interpretation. The follow-up duration reflects clinical outcome tracking rather than drug exposure duration.
Result: Observational association
Evidence strength: Observational
Notes / limitations: Clinical follow-up duration is not the same as pharmacokinetic duration.
IV exposure in a 2-person pilot safety study:
A pilot study evaluated short-term IV BPC-157 safety in 2 healthy adults with laboratory monitoring over a brief protocol (Research). The study reported no side effects and no measurable changes in tested biomarkers, but the sample size was too small to characterize general safety or pharmacokinetics (Research). This source is useful for documenting a human IV research context, but it does not provide a robust human half-life or Tmax estimate. It should not be interpreted as evidence that IV BPC-157 is broadly safe.
Result: Neutral overall findings
Evidence strength: Emerging
Notes / limitations: A 2-person safety pilot cannot establish population-level safety or PK.
Preclinical IV and IM exposure — animal PK context only:
Animal ADME research in rats and beagle dogs reported rapid BPC-157 elimination after IV and IM dosing, with half-life generally under 30 minutes (Research). The same study reported IM bioavailability of about 14–19% in rats and 45–51% in beagle dogs, showing species- and route-dependent systemic exposure (Research). These numbers are valuable for structured pharmacokinetic context, but they should not be treated as human half-life, human Tmax, or human bioavailability. The animal data also help explain why formulation and route may matter for peptide exposure.
Result: Preliminary signal
Evidence strength: Emerging
Notes / limitations: These are animal PK values and should not be converted into human dosing or timing guidance.
Key Takeaways from Human Research
- BPC-157 has a small human evidence base, and the best-supported conclusion is that clinical evidence remains preliminary rather than mature (Review).
- Joint Health evidence includes a retrospective knee-pain chart review with reported improvement, but the study lacks randomized placebo control and standardized outcome structure (Research).
- Urinary Health evidence includes a small interstitial-cystitis pilot study with reported symptom improvement, but the sample size and design limit confidence (Research).
- Muscle Health evidence includes a registered Phase 2 hamstring-strain trial, but a registry record is not the same as published efficacy evidence (Research).
- Human pharmacokinetic values such as Tmax and half-life are not well established in accessible peer-reviewed human publications, while animal data report rapid elimination and half-life generally under 30 minutes (Research).
- FDA materials identify compounded BPC-157 as a safety concern because of immunogenicity and peptide-quality issues (FDA).
Origin & Natural Occurrence
BPC-157 is described in reviews as a stable gastric pentadecapeptide related to a peptide sequence isolated from human gastric juice (Review). It is not a conventional dietary ingredient with ordinary food-intake ranges, and the BPC-157 studied in research contexts is a synthetic peptide preparation (Review).
The peptide is commonly discussed as “body protection compound 157,” but that phrase should be treated as a research name rather than a proven clinical-effect statement (Review). Manufacturing and formulation quality are especially relevant because the FDA has raised peptide-related concerns for compounded BPC-157, including immunogenicity and impurity-related risk considerations (FDA).
How It Behaves in the Body
BPC-157 is a peptide, which means it is built from amino acids and may be handled differently by the body depending on whether it is taken orally, injected, or placed locally into a tissue or cavity. Published human PK parameters such as plasma half-life, Tmax, and oral bioavailability were not verified in accessible peer-reviewed human studies for this article, so human timing claims should remain cautious (Research).
The best numerical PK information comes from animal ADME research in rats and beagle dogs. In that study, BPC-157 showed rapid elimination after IV and IM dosing, with reported half-life generally under 30 minutes and IM bioavailability of about 14–19% in rats and 45–51% in beagle dogs (Research). These values suggest route- and species-dependent exposure, but they cannot be assumed to represent human half-life or human bioavailability (Research).
A short measured blood half-life does not necessarily prove a short biological effect, because tissue-level signaling or downstream biological responses can last longer than detectable plasma exposure. For BPC-157, however, human studies have not yet mapped plasma concentration, tissue exposure, onset, and clinical response with enough detail to establish a reliable pharmacokinetic-pharmacodynamic profile (Review).
Absorption & Delivery Formats
Oral immediate-release
A Phase 1 oral safety and pharmacokinetics trial record described oral BPC-157 testing in healthy adults, but peer-reviewed completed human PK values were not verified for this article (Research). Oral Tmax, oral half-life, and oral bioavailability should therefore be described as not established in accessible human publications.
Oral extended-release
No verified human evidence for an oral extended-release BPC-157 formulation was identified in the source set used for this article. Because route and formulation may meaningfully affect peptide exposure, extended-release claims should not be inferred from animal IV or IM data (Research).
Sublingual
No verified human sublingual BPC-157 pharmacokinetic study was identified in the source set used for this article. Sublingual absorption should therefore be treated as uncharacterized unless supported by direct human PK data.
Transdermal
No verified human transdermal BPC-157 pharmacokinetic study was identified in the source set used for this article. Transdermal exposure should not be assumed from injectable, intravesical, or animal PK data.
Injectable / IV (research or clinical only)
A 2-person IV pilot safety study reported no short-term side effects or major biomarker changes, but it was not sufficient to establish human IV half-life, Tmax, or population-level safety (Research). Animal IV and IM data reported rapid elimination and half-life generally under 30 minutes, but those results are preclinical and species-specific (Research).
Intravesical / intra-articular clinical exposure
Human reports include intravesical exposure in interstitial cystitis and intra-articular exposure in knee pain, but these studies measured symptoms rather than full pharmacokinetic profiles (Research) (Research). These routes should be described as clinical research contexts rather than validated delivery formats with established bioavailability.
Quick Facts at a Glance
Onset (reported)
Human pharmacologic onset is not established from published PK data. The available human studies describe symptom or safety outcomes after local or IV exposure, but they do not define a verified onset time for BPC-157 action (Research) (Research).
Time to peak (Tmax)
Human Tmax was not verified in accessible peer-reviewed publications. A registered oral Phase 1 study was designed to examine pharmacokinetics in healthy adults, but completed peer-reviewed Tmax values were not confirmed in the source set used here (Research).
Half-life (t½)
Human half-life was not verified in accessible peer-reviewed publications. In rat and beagle-dog ADME research, BPC-157 showed rapid elimination after IV and IM dosing, with reported half-life generally under 30 minutes, which should be cited as animal PK context rather than human half-life (Research).
Typical duration
Typical human pharmacologic duration is not established. Human knee-pain and interstitial-cystitis studies measured clinical outcomes over follow-up periods, and those outcome windows cannot be equated with plasma exposure duration or half-life (Research) (Research).
Absorption routes studied
Human research and trial records include oral, IV, intra-articular, and intravesical contexts, but route-specific human bioavailability was not verified in published PK data (Research) (Research). Animal research suggests systemic exposure differs by route and species, with IM bioavailability reported at about 14–19% in rats and 45–51% in beagle dogs (Research).
Formulation differences
Formulation differences are likely important because BPC-157 is a peptide and because animal systemic exposure differed by route and species. Comparative human formulation studies were not verified in the source set, so formulation claims should remain limited and evidence-qualified (Research).
Variability drivers
The clearest documented variability drivers are route of administration, species, and pharmacokinetic assay context from animal ADME research (Research). Human variability drivers such as body size, disease state, route, local tissue condition, peptide quality, and metabolism have not been well quantified in verified human PK studies.
Tolerance / adaptation
Human tolerance or adaptation patterns are not established. The available human studies are too small, uncontrolled, or short-term to define repeated-exposure tolerance or loss of effect over time (Research).
Evidence strength snapshot
BPC-157 has limited human clinical evidence and more developed animal pharmacokinetic evidence. The most precise numerical timing data currently come from animal ADME research rather than published human PK trials (Review) (Research).
Other Physiological Contexts Studied (If Applicable)
Human physiological contexts beyond Joint Health, Urinary Health, Muscle Health, Pain and Acute Inflammation, and Digestive and Gastrointestinal Health were not sufficiently verified for separate condition-level coverage in this article. The broader BPC-157 literature contains many preclinical tissue-repair and mechanistic models, but reviews consistently describe the human evidence base as limited (Review) (Review).
Safety, Interactions & Regulation
Published human safety evidence for BPC-157 is very limited. A 2-person IV pilot study reported no short-term side effects and no major changes in measured heart, liver, kidney, thyroid, or glucose biomarkers, but this sample size cannot characterize general safety across populations (Research).
The FDA has identified BPC-157 among bulk drug substances that may present significant safety risks when used in compounding, including immunogenicity concerns and limited safety information for proposed administration routes (FDA). The FDA also scheduled BPC-157-related bulk substances for Pharmacy Compounding Advisory Committee discussion in relation to the 503A Bulks List and an evaluated-use context including ulcerative colitis (FDA).
Interaction data are not well characterized in verified human studies. Because BPC-157 is a peptide with limited human PK and safety characterization, interaction claims should not be made without direct evidence.
Population-specific safety data are also limited. The available human evidence does not adequately characterize safety in pregnancy, lactation, adolescents, older adults, people with cancer, people with immune disorders, or people using multiple medications.
EU regulatory status is not stated as a direct authorization conclusion here because no direct EMA or EFSA BPC-157-specific source was verified for this article. A literature and patent review states that BPC-157 is not approved for standard medical use by FDA or other global regulators, but that review should not substitute for direct EU regulatory documentation (Review).
Evidence Overview
The overall human evidence base for BPC-157 is Emerging, with small human studies in Joint Health and Urinary Health, trial-registration evidence in Muscle Health, and limited short-term IV safety data. The strongest numerical pharmacokinetic evidence is not human evidence; it comes from animal ADME research reporting rapid elimination and half-life generally under 30 minutes. Confidence is not higher because the published human evidence is sparse, small, often uncontrolled, and not yet supported by multiple large randomized trials (Research) (Research) (Research).
Joint Health evidence is based mainly on a retrospective knee-pain chart review that reported improvement in most followed patients receiving BPC-157 alone. This type of evidence can identify a possible clinical signal, but it cannot determine whether the observed improvement was caused by BPC-157 because there was no randomized placebo comparison (Research).
Urinary Health evidence includes a small pilot study in interstitial cystitis. The study reported symptom improvement, but the small sample and preliminary design mean that replication and controlled testing would be needed before confidence could become moderate or strong (Research).
Muscle Health evidence includes a registered Phase 2 trial in acute hamstring strain. Registry information is useful for identifying research direction and planned outcomes, but it does not establish clinical efficacy unless completed results are published and verified (Research).
Pharmacokinetic interpretation is constrained by the gap between animal and human data. Animal ADME research provides useful numerical values, including rapid elimination, half-life generally under 30 minutes, and species-dependent IM bioavailability, but these values should not be presented as human PK estimates (Research).
Regulatory and safety context further limits strong conclusions. FDA materials identify compounded BPC-157 as a potential safety concern, and reviews state that the compound remains investigational because human evidence is minimal (FDA) (Review).
Evidence Confidence Classification
Emerging is the appropriate overall evidence classification for BPC-157 because published human studies are few, small, and not yet supported by multiple replicated randomized trials (Review). The human evidence includes observational or pilot findings in Joint Health and Urinary Health, a 2-person IV safety pilot, and registered trial records rather than mature clinical evidence (Research) (Research). The pharmacokinetic evidence contains useful animal numbers, including half-life generally under 30 minutes, but these data do not establish human half-life or human bioavailability (Research).
Similar Ingredients & Comparators
Similar supplement-style or research-context ingredients:
- Collagen peptides
- Gelatin-derived peptides
- Glycine
- Proline
- Glucosamine
- Chondroitin sulfate
- Hyaluronic acid
- Curcumin
- Omega-3 fatty acids
- MSM
- Creatine
Medical / pharma comparator categories:
- Injectable biologics
- Wound-healing agents
- Anti-inflammatory medicines
- Pain-management medicines
- Orthobiologic procedures
- Bladder-pain therapies
- Gastrointestinal anti-inflammatory therapies
Combination Context
No evidence-qualified ingredient combinations were identified in the verified human BPC-157 source set. Human studies and trial records reviewed here focused on BPC-157 exposure contexts rather than ingredient combinations (Research) (Research).
BPC-157 + other ingredients:
No verified human study in this source set established a specific supplement-style ingredient combination with BPC-157. Combination claims should therefore be treated as unsupported unless a direct human study is available (Review).
FAQ
What is BPC-157?
BPC-157 is a synthetic pentadecapeptide related to a peptide sequence described from human gastric juice (Review). It is studied mainly as an experimental peptide rather than as a conventional food nutrient or established supplement ingredient (Review). Its human evidence base is limited and should not be confused with the larger animal literature (Review).
What does human research study BPC-157 for?
Human research has studied or registered BPC-157 in Joint Health, Urinary Health, Muscle Health, Pain and Acute Inflammation, and safety/PK contexts (Research) (Research). Published human studies include a knee-pain chart review, an interstitial-cystitis pilot study, and a 2-person IV safety pilot (Research) (Research). Registered trials indicate additional research interest, but registry records do not prove clinical benefit (Research).
What are the best-supported uses?
No use of BPC-157 is strongly supported by mature human clinical evidence in the source set used for this article (Review). The most developed human signals are preliminary findings in Joint Health and Urinary Health, but both rely on small or uncontrolled evidence (Research) (Research). These findings are best described as early research signals rather than established uses.
Where is evidence mixed or limited?
Evidence is limited across all human BPC-157 domains because studies are few, small, and often uncontrolled (Review). Human pharmacokinetic evidence is especially limited because verified peer-reviewed human Tmax, half-life, and oral bioavailability values were not identified in this source set (Research). Animal PK numbers are useful for context but should not be treated as human estimates (Research).
How quickly does BPC-157 act?
Human pharmacologic onset is not established from published PK data. Available human studies measured symptom outcomes or short-term safety findings rather than verified onset timing (Research) (Research). Animal ADME data show rapid elimination, but elimination half-life is not the same as onset of effect (Research).
What is the half-life of BPC-157?
Human half-life was not verified in accessible peer-reviewed human PK publications for this article. Animal ADME research in rats and beagle dogs reported rapid elimination after IV and IM dosing, with half-life generally under 30 minutes (Research). These animal values are useful for structured PK context but should not be presented as confirmed human half-life.
What affects absorption and variability?
The most clearly documented variability factors are route of administration, species, and assay context in animal ADME research (Research). Human route-specific bioavailability has not been well verified in peer-reviewed PK publications, so absorption claims should remain cautious (Research). Peptide quality and formulation may also matter, and the FDA has raised peptide-quality and immunogenicity concerns for compounded BPC-157 (FDA).
Is tolerance reported?
Human tolerance or adaptation patterns are not established for BPC-157. The available human studies are too small, uncontrolled, or short-term to define repeated-exposure tolerance (Research). No stable tolerance conclusion should be drawn without larger and longer human studies.
Why do studies disagree or remain hard to interpret?
BPC-157 studies are hard to interpret because human research uses different routes, populations, and outcome types (Research) (Research). The evidence also mixes animal pharmacokinetic data with small human clinical reports, which can create confusion if species differences are not clearly labeled (Research). Reviews emphasize that human evidence remains minimal compared with preclinical work (Review).
What ingredients is BPC-157 commonly combined with and why?
No evidence-qualified human ingredient-combination pattern was identified in the source set used for this article. Human BPC-157 studies reviewed here did not establish a specific supplement-style combination framework (Research) (Research). Combination claims should therefore be avoided unless directly supported by human research.
What foods naturally contain BPC-157?
BPC-157 is not a conventional food nutrient with established dietary intake ranges. Reviews describe it as related to a peptide sequence from human gastric juice, while research preparations are synthetic peptide forms (Review). No ordinary food source can be cited as a verified dietary source of research-grade BPC-157 in the evidence used for this article.
How is BPC-157 regulated?
In the United States, the FDA has identified BPC-157 among bulk drug substances that may present significant safety risks when used in compounding (FDA). FDA materials cite concerns including immunogenicity and limited safety information for proposed routes of administration (FDA). A direct EMA or EFSA BPC-157-specific authorization source was not verified for this article, so EU status should be described cautiously rather than inferred.
Resources
BPC-157 knee pain chart review — PubMed — https://pubmed.ncbi.nlm.nih.gov/34324435/
BPC-157 interstitial cystitis pilot study — PubMed — https://pubmed.ncbi.nlm.nih.gov/39325560/
BPC-157 IV safety pilot study — PubMed — https://pubmed.ncbi.nlm.nih.gov/40131143/
BPC-157 animal ADME pharmacokinetics study — PMC — https://pmc.ncbi.nlm.nih.gov/articles/PMC9794587/
Orthopaedic sports medicine systematic review — PubMed — https://pubmed.ncbi.nlm.nih.gov/40756949/
Musculoskeletal healing narrative review — PubMed — https://pubmed.ncbi.nlm.nih.gov/40789979/
Literature and patent review — PubMed — https://pubmed.ncbi.nlm.nih.gov/40005999/
PCO-02 oral safety and pharmacokinetics trial record — Veeva CTV — https://ctv.veeva.com/study/pco-02-safety-and-pharmacokinetics-trial
Acute hamstring strain trial record — ClinicalTrials.gov — https://clinicaltrials.gov/study/NCT07437547
FDA compounded-substance safety-risk page — FDA — https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
FDA Pharmacy Compounding Advisory Committee meeting page — FDA — https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
More from the Supplement Ingredients & Medical Ingredients Encyclopedia
